3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Phase 1/2
1
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Breast
1
Conditions
Breast Neoplasms
49
Carcinoma, Renal Cell
30
Neoplasm Metastasis
18
Neoplasms
15
Kidney Neoplasms
14
Neuroendocrine Tumors
11
Carcinoma, Neuroendocrine
9
Prostatic Neoplasms
7
Melanoma
7
Triple Negative Breast Neoplasms
6
Thyroid Neoplasms
6
Sarcoma
6
Meningioma
6
Lymphoma
6
Glioma
6
Endometrial Neoplasms
6
Tuberous Sclerosis
5
Stomach Neoplasms
5
Recurrence
5
Lymphoma, Mantle-Cell
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma, Large B-Cell, Diffuse
4
Liver Neoplasms
4
Carcinoma, Islet Cell
4
Astrocytoma
4
Interventions
Oxaliplatin
10
Capecitabine
9
Cisplatin
8
Fluorouracil
5
Leucovorin
4
Bevacizumab
4
tegafur-gimeracil-oteracil
3
pemigatinib
3
atezolizumab
3
Nivolumab
3
trebananib
2
ponatinib
2
pembrolizumab
2
avelumab
2
apatinib
2
alectinib
2
XELOX
2
Standard of Care
2
S 1 (combination)
2
Radiotherapy
2
Radiosurgery
2
Ocoxin
2
Irinotecan
2
Ipilimumab
2
Gemcitabine
2
Folfox protocol
2
Everolimus
2
Erlotinib Hydrochloride
2
Acupuncture Therapy
2
zanidatamab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Gastrointestinal Neoplasms
×
Everolimus
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled
NCT01567488
2018-01-03
EVERLAR
Grupo Espanol de Tumores Neuroendocrinos
Phase 2
Completed
43 enrolled